Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of March 11, 2024

ByJessica Jones

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more.

Read the full coverage here:

Race identified as risk factor for VTE after pulmonary resection for lung cancer

FDA approves Rybrevant for treatment of non-small cell lung cancer

Behavioral health disorders have a ‘big impact’ on cancer surgery outcomes

Optimizing immunotherapy, biomarker testing vital to progress in lung cancer treatment

FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer

References:

Axtell AL, et al. Ann Thorac Surg. 2024;doi:10.1016/j.athoracsur.2024.01.005.

Katayama ES, et al. J Am Coll Surgeons. 2024;doi:10.1097/XCS.0000000000000954.

Press Release

Published by:

Sources/Disclosures

Collapse

Disclosures: Please see each study for relevant financial disclosures.

Read more

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of March 11, 2024

Healio Minute: Lung Cancer Edition

Related Content